Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16901842 | 0.83 | ALDH1A1 (0.41) | ADRA1DADRA1AADRA1BALDH1A1DPP4 | |
| SCHEMBL16901841 | 0.79 | DPP4 (0.45) | ADRA1DADRA1AADRA1BALDH1A1DPP4 | |
| SCHEMBL3229983 | 0.76 | ALDH1A1 (0.39) | ADRA1DADRA1AADRA1BALDH1A1DPP4 | |
| SCHEMBL8185448 | 0.75 | — | — | |
| SCHEMBL9900205 | 0.74 | ADRA1D (0.43) | ADRA1DADRA1AADRA1BALDH1A1DPP4 | |
| SCHEMBL16901837 | 0.73 | ALDH1A1 (0.37) | ADRA1DADRA1AADRA1BALDH1A1DPP4 | |
| SCHEMBL19434555 | 0.69 | MRGPRX4 (0.51) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL7130916 | 0.68 | MAPT (0.39) | ADRA1DADRA1AADRA1BALDH1A1DPP4 | |
| SCHEMBL12664443 | 0.67 | ALDH1A1 (0.41) | ADRA1DADRA1AADRA1BALDH1A1DPP4 | |
| SCHEMBL3176922 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | SHIRAKI HIROAKI | 2010-04-01 | — | — | US | disclosed |
| EP-1857455-A1 | CINNAMOYL COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1857455-A1 | CINNAMOYL COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081652-A1 | Cinnamoyl Compound and Use Thereof | COL2A1, MMP7, COL14A1 | ADRA1D 4229/4885ADRA1A 4067/4885ADRA1B 2939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.